INC.;PRESIDENT AND FELLOWS OF HARVARD COLLEGE;DANA-FARBER CANCER INSTITUTE;MASSACHUSETTS INSTITUTE OF TECHNOLOGY;HOWARD HUGHES MEDICAL INSTITUTE;DANA-FARBER CANCER INSTITUTE, INC.
The present disclosure relates to reagents (antigenic and/or immunogenic reagents) and kits that are useful in a variety of in vitro, in vivo, and ex vivo methods including, e.g., methods for inducing an immune response, or for generating an antibody, in a subject. The reagents described herein can be used in the treatment or prevention of HIV-1 infections. In addition, the disclosure provides methods and compositions useful for designing (or identifying) an agent that binds to an membrane proximal external region (MPER) of an HIV-1 gp160 polypeptide or an agent that inhibits the fusion of an HIV-1 particle to a cell.
